| 000 | 01034cam a2200253 i 4500 | ||
|---|---|---|---|
| 005 | 20170329112320.0 | ||
| 008 | 131029t20142014ne a b 001 0 eng | ||
| 020 | _a9780123820303 (alk. paper) | ||
| 020 | _a0123820308 (alk. paper) | ||
| 041 | _aeng | ||
| 082 | 0 | 0 |
_a615.19 _bSIL |
| 100 | 1 |
_aSilverman, Richard B., _914895 |
|
| 245 | 1 | 4 |
_aThe organic chemistry of drug design and drug action. / _c by Richard B. Silverman, Mark W. Holladay. |
| 250 | _a3rd edition / | ||
| 260 |
_aWaltham, _bElsevier; _c2014 |
||
| 300 |
_axviii, 517 p : _epbk, |
||
| 505 | 0 | _aIntroduction -- Lead discovery and lead modification -- Receptors -- Enzymes -- Enzyme inhibition and inactivation -- Dna-interactive agents -- Drug resistance and drug synergism -- Drug metabolism -- Prodrugs and drug delivery systems. | |
| 650 | 0 |
_aPharmaceutical chemistry. _914896 |
|
| 650 | 0 |
_aBioorganic chemistry. _914897 |
|
| 650 | 0 |
_aMolecular pharmacology. _914898 |
|
| 650 | 0 |
_aDrugs _xDesign. _914899 |
|
| 700 | 1 |
_aHolladay, Mark W., _914900 |
|
| 942 | _cBK | ||
| 999 |
_c33088 _d33088 |
||